Distribution and factors associated with salivary secretory leukocyte protease inhibitor concentrations

doi:10.1111/odi.12550

. 2016 Nov;22(8):781-790.

doi: 10.1111/odi.12550. Epub 2016 Aug 17.

Distribution and factors associated with salivary secretory leukocyte protease inhibitor concentrations

S Rahman^{1

2}, C M Pierce Campbell³, B N Torres⁴, M T O'Keefe⁵, D J Ingles⁶, L L Villa⁷, R J Carvalho da Silva⁸, R C Cintra⁹, E Lazcano-Ponce¹⁰, J Salmeron^{10

11}, M Quiterio¹⁰, A R Giuliano²

Affiliations

¹ Department of Epidemiology and Biostatistics, College of Public Health, University of South Florida, Tampa, FL, USA.
² Department of Cancer Epidemiology, Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
³ Department of Cancer Epidemiology, Moffitt Cancer Center and Research Institute, Tampa, FL, USA. christine.piercecampbell@moffitt.org.
⁴ Department of Biostatistics, Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
⁵ Department of Performance Improvement, Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
⁶ Vanderbilt Institute for Global Health, Nashville, TN, USA.
⁷ Department of Radiology & Oncology, School of Medicine, University of São Paulo, São Paulo, Brazil.
⁸ Centro de Referencia e Treinamento em DST/Aids, São Paulo, Brazil.
⁹ Department of Biochemistry, Chemistry Institute, University of São Paulo, São Paulo, Brazil.
¹⁰ Instituto Nacional de Salúd Publica, Cuernavaca, Mexico.
¹¹ Instituto Mexicano del Seguro Social, Cuernavaca, Mexico.

PMID: 27470907
PMCID: PMC5056814
DOI: 10.1111/odi.12550

Distribution and factors associated with salivary secretory leukocyte protease inhibitor concentrations

S Rahman et al. Oral Dis. 2016 Nov.

. 2016 Nov;22(8):781-790.

doi: 10.1111/odi.12550. Epub 2016 Aug 17.

Authors

Affiliations

¹ Department of Epidemiology and Biostatistics, College of Public Health, University of South Florida, Tampa, FL, USA.
² Department of Cancer Epidemiology, Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
³ Department of Cancer Epidemiology, Moffitt Cancer Center and Research Institute, Tampa, FL, USA. christine.piercecampbell@moffitt.org.
⁴ Department of Biostatistics, Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
⁵ Department of Performance Improvement, Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
⁶ Vanderbilt Institute for Global Health, Nashville, TN, USA.
⁷ Department of Radiology & Oncology, School of Medicine, University of São Paulo, São Paulo, Brazil.
⁸ Centro de Referencia e Treinamento em DST/Aids, São Paulo, Brazil.
⁹ Department of Biochemistry, Chemistry Institute, University of São Paulo, São Paulo, Brazil.
¹⁰ Instituto Nacional de Salúd Publica, Cuernavaca, Mexico.
¹¹ Instituto Mexicano del Seguro Social, Cuernavaca, Mexico.

PMID: 27470907
PMCID: PMC5056814
DOI: 10.1111/odi.12550

Abstract

Objectives: This cross-sectional study examined the distribution and correlates of salivary secretory leukocyte protease inhibitor (SLPI) concentrations within a multinational cohort of men.

Methods: Extracellular SLPI was measured in oral gargle cell supernatants of 378 men from three countries using an ELISA-based assay. Risk factor data were collected by a questionnaire. Factors associated with SLPI were assessed using linear and logistic regression for continuous and categorical SLPI, respectively.

Results: Among men aged 18-73 years, the median SLPI concentration was 492.0 ng ml^-1 (range: 2.3-1919.9). In multivariable modeling, men in Brazil and younger men (18-30 years) were more likely to have higher levels of SLPI [adjusted odds ratio (aOR) 3.84; 95% confidence interval (CI): 1.94-7.59, and aOR 3.84; 95% CI: 1.98-7.43, respectively]. Men with a self-reported sexually transmitted diseases diagnosis in the past 6 months were more likely to have higher SLPI levels (aOR 2.98; 95% CI: 1.1-7.83) and men reporting bleeding/swollen gums were less likely to have higher SLPI (aOR 0.34; 95% CI: 0.15-0.79). Similar results were observed for linear regression models.

Conclusions: Secretory leukocyte protease inhibitor concentrations varied significantly by country and decreased with increasing age. The interaction between SLPI, modifiable factors, and oral infections that influence cancer risk warrants further investigation.

Keywords: HIM Study; immune system protein; saliva; secretory leukocyte protease inhibitor.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interests None to declare.

References

1. Abraham LA, Chinni C, Jenkins AL, Lourbakos A, Ally N, Pike RN, Mackie EJ. Expression of protease-activated receptor-2 by osteoblasts. Bone. 2000;26:7–14. - PubMed
1. Adapala VJ, Buhman KK, Ajuwon KM. Novel anti-inflammatory role of SLPI in adipose tissue and its regulation by high fat diet. J Inflamm (Lond) 2011;8:5. - PMC - PubMed
1. Bouloukaki I, Tsiligianni IG, Tsoumakidou M, Mitrouska I, Prokopakis EP, Mavroudi I, Siafakas NM, Tzanakis N. Sputum and nasal lavage lung-specific biomarkers before and after smoking cessation. BMC Pulm Med. 2011;11:35. - PMC - PubMed
1. Castellsague X, Alemany L, Quer M, Halec G, Quiros B, Tous S, Clavero O, Alos L, Biegner T, Szafarowski T, Alejo M, Holzinger D, Cadena E, Claros E, Hall G, Laco J, Poljak M, Benevolo M, Kasamatsu E, Mehanna H, Ndiaye C, Guimera N, Lloveras B, Leon X, Ruiz-Cabezas JC, Alvarado-Cabrero I, Kang CS, Oh JK, Garcia-Rojo M, Iljazovic E, Ajayi OF, Duarte F, Nessa A, Tinoco L, Duran-Padilla MA, Pirog EC, Viarheichyk H, Morales H, Costes V, Felix A, Germar MJ, Mena M, Ruacan A, Jain A, Mehrotra R, Goodman MT, Lombardi LE, Ferrera A, Malami S, Albanesi EI, Dabed P, Molina C, Lopez-Revilla R, Mandys V, Gonzalez ME, Velasco J, Bravo IG, Quint W, Pawlita M, Munoz N, Sanjose S, Xavier Bosch F. HPV Involvement in Head and Neck Cancers: Comprehensive Assessment of Biomarkers in 3680 Patients. Journal of the National Cancer Institute. 2016;108 - PubMed
1. Chattopadhyay A, Gray LR, Patton LL, Caplan DJ, Slade GD, Tien HC, Shugars DC. Salivary secretory leukocyte protease inhibitor and oral candidiasis in human immunodeficiency virus type 1-infected persons. Infect Immun. 2004;72:1956–63. - PMC - PubMed

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

Grants and funding

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations
Miscellaneous
- NCI CPTAC Assay Portal

[1] Abraham LA, Chinni C, Jenkins AL, Lourbakos A, Ally N, Pike RN, Mackie EJ. Expression of protease-activated receptor-2 by osteoblasts. Bone. 2000;26:7–14. - PubMed

[2] Abraham LA, Chinni C, Jenkins AL, Lourbakos A, Ally N, Pike RN, Mackie EJ. Expression of protease-activated receptor-2 by osteoblasts. Bone. 2000;26:7–14. - PubMed

[3] Adapala VJ, Buhman KK, Ajuwon KM. Novel anti-inflammatory role of SLPI in adipose tissue and its regulation by high fat diet. J Inflamm (Lond) 2011;8:5. - PMC - PubMed

[4] Adapala VJ, Buhman KK, Ajuwon KM. Novel anti-inflammatory role of SLPI in adipose tissue and its regulation by high fat diet. J Inflamm (Lond) 2011;8:5. - PMC - PubMed

[5] Bouloukaki I, Tsiligianni IG, Tsoumakidou M, Mitrouska I, Prokopakis EP, Mavroudi I, Siafakas NM, Tzanakis N. Sputum and nasal lavage lung-specific biomarkers before and after smoking cessation. BMC Pulm Med. 2011;11:35. - PMC - PubMed

[6] Bouloukaki I, Tsiligianni IG, Tsoumakidou M, Mitrouska I, Prokopakis EP, Mavroudi I, Siafakas NM, Tzanakis N. Sputum and nasal lavage lung-specific biomarkers before and after smoking cessation. BMC Pulm Med. 2011;11:35. - PMC - PubMed

[7] Castellsague X, Alemany L, Quer M, Halec G, Quiros B, Tous S, Clavero O, Alos L, Biegner T, Szafarowski T, Alejo M, Holzinger D, Cadena E, Claros E, Hall G, Laco J, Poljak M, Benevolo M, Kasamatsu E, Mehanna H, Ndiaye C, Guimera N, Lloveras B, Leon X, Ruiz-Cabezas JC, Alvarado-Cabrero I, Kang CS, Oh JK, Garcia-Rojo M, Iljazovic E, Ajayi OF, Duarte F, Nessa A, Tinoco L, Duran-Padilla MA, Pirog EC, Viarheichyk H, Morales H, Costes V, Felix A, Germar MJ, Mena M, Ruacan A, Jain A, Mehrotra R, Goodman MT, Lombardi LE, Ferrera A, Malami S, Albanesi EI, Dabed P, Molina C, Lopez-Revilla R, Mandys V, Gonzalez ME, Velasco J, Bravo IG, Quint W, Pawlita M, Munoz N, Sanjose S, Xavier Bosch F. HPV Involvement in Head and Neck Cancers: Comprehensive Assessment of Biomarkers in 3680 Patients. Journal of the National Cancer Institute. 2016;108 - PubMed

[8] Castellsague X, Alemany L, Quer M, Halec G, Quiros B, Tous S, Clavero O, Alos L, Biegner T, Szafarowski T, Alejo M, Holzinger D, Cadena E, Claros E, Hall G, Laco J, Poljak M, Benevolo M, Kasamatsu E, Mehanna H, Ndiaye C, Guimera N, Lloveras B, Leon X, Ruiz-Cabezas JC, Alvarado-Cabrero I, Kang CS, Oh JK, Garcia-Rojo M, Iljazovic E, Ajayi OF, Duarte F, Nessa A, Tinoco L, Duran-Padilla MA, Pirog EC, Viarheichyk H, Morales H, Costes V, Felix A, Germar MJ, Mena M, Ruacan A, Jain A, Mehrotra R, Goodman MT, Lombardi LE, Ferrera A, Malami S, Albanesi EI, Dabed P, Molina C, Lopez-Revilla R, Mandys V, Gonzalez ME, Velasco J, Bravo IG, Quint W, Pawlita M, Munoz N, Sanjose S, Xavier Bosch F. HPV Involvement in Head and Neck Cancers: Comprehensive Assessment of Biomarkers in 3680 Patients. Journal of the National Cancer Institute. 2016;108 - PubMed

[9] Chattopadhyay A, Gray LR, Patton LL, Caplan DJ, Slade GD, Tien HC, Shugars DC. Salivary secretory leukocyte protease inhibitor and oral candidiasis in human immunodeficiency virus type 1-infected persons. Infect Immun. 2004;72:1956–63. - PMC - PubMed

[10] Chattopadhyay A, Gray LR, Patton LL, Caplan DJ, Slade GD, Tien HC, Shugars DC. Salivary secretory leukocyte protease inhibitor and oral candidiasis in human immunodeficiency virus type 1-infected persons. Infect Immun. 2004;72:1956–63. - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Distribution and factors associated with salivary secretory leukocyte protease inhibitor concentrations

Affiliations

Distribution and factors associated with salivary secretory leukocyte protease inhibitor concentrations

Authors

Affiliations

Abstract

Conflict of interest statement

Similar articles

References

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources

Miscellaneous